Litmus Equity exists to make a positive difference in people’s lives by commercialising companies that are solving society’s most significant issues and delivering exceptional investor returns.
Founded by a team with decades of investment management and private equity experience, Litmus Equity exists to make a positive difference to people’s lives by commercialising companies that are solving the most significant issues facing society and by delivering exceptional investor returns.
We all know that scientific discoveries hold the key to solving some of these issues. But unfortunately, many of these breakthroughs never make it out of the lab and into commercially successful businesses where they can do the most good.
We believe that by supporting these businesses, we can help to accelerate positive change and make a real impact on the issues that matter most
Our emphasis is on active management which seeks out undervalued companies and, where appropriate, high-value impact investing, which has the potential to create the best returns. We have some key investment aspects that we seek out in every potential investment to reduce the risk to investors;
*There must be no science risk, the science behind the core technology has to have been proven, there is no more research
*There is a seasoned and experienced management team behind the defined pathway to revenues
*There is a large target market for the products/services
*The technology is protected, and it is difficult to copy
We believe that the application of human skill, knowledge, and experience to the process of investment selection and monitoring, adds significant value to investors.
Litmus Equity will only target investment into private companies where we look to find high-tech businesses with scaleable, highly innovative, and often disruptive technology.
Our approach to investing is centered around three unstoppable trends that we believe will shape the future of our planet. They are:
Changing values and behaviours
Climate change and resource scarcity
Shifting demographics and improving quality of life
We’ll help you to achieve sustainable growth and development through technological innovation and productivity, leading to the sustainable growth and development of a company, an industry – and the nation.
With these occurring trends in mind, we believe we should focus our investment attention on companies in the following industries
Health and Wellness
Predictive and preventative healthcare
Therapeutics, devices and diagnostics
Medical Infrastructure and service delivery
Genetics
Sustainable mining
Director Peter is a highly experienced and respected Senior Executive and Director with a 30 year history in Corporate Finance and Merchant Banking. Peter has been involved in Venture Capital through establishing the listed VC group SME Growth Limited and raising A$28 million in capital via the Australian Stock Exchange. He was a Director on the Investment Committee responsible for approving the direct investment of capital in Investees; as Head of the Investment Review Committee Peter reviewed the performance of each of the 14 investments on a quarterly basis. All the businesses have progressed including:
Peter has been involved in listing and acquisitions on the ASX including successfully representing Viterra Inc as Chairman of the Australian acquirer, in its A$1.6 billion public takeover of ABB Grain.
Peter has extensive experience as an investment director, in management and consultancy ranging from large corporations and financial institutions to small or family run businesses.
Litmus Equity has access to several Aged Care projects across Australia. If you would like to learn more about these projects, please contact us directly for further information.
Biosceptre is a Cambridge University UK-based clinical-stage immuno–oncology company that has identified a novel and valuable cancer target marker (nfP2X7) that only appears on the cell surface of a wide range of cancers including Lung, Breast, Colorectal, and Prostate, but is absent in healthy tissue.
Biosceptre has developed a CAR-T immunotherapy targeting the nfP2X7 marker. CAR-T therapy is a form of immunotherapy that uses specially altered T cells to fight cancer. With CAR-T, white blood cells are removed and “trained" to recognise and kill cancer cells bearing the nfP2X 7 target.
Biosceptre has successfully closed its latest £7million 2021 raise and is seeking a PreIPO raise of £200 million (USD$272 mill) and continues to achieve increasing T-cell killing capacity utilising their technology. As a result of the latest test data results the current valuation for Biosceptre pre-IPO has risen to £302million
(USD$401 million).
The Directors are intending to undertake the IPO on the Nasdaq towards the end of 2024. In discussions with New York based broking houses, the company will be offering the IPO at a valuation of between USD$2.5billion to USD$3.5Billion.
The Company is funding to (a) retire the Australian Govt substantial equity position in the company at market competitive pricing (it has been in place for 10 years), and (b) to raise further working funds to pursue the commercialisation of MiCheck ® in key markets (China/USA) and will allow finalisation of manufacturing as well as the rollout of the test via centralised laboratories.
Minomic is an immuno-oncology company founded in Sydney in 2007, which has developed a definitive diagnostic blood test for the early detection of prostate cancer – the MiCheck ® test. Clinical Studies have demonstrated significantly improved performance over existing prostate cancer testing with a 95% Sensitivity Result.